The effects of augmented renal clearance on the pharmacokinetic/pharmacodynamic profile of piperacillin/tazobactam in children and young adults with malignant or non-malignant haematological or oncological diagnosis - The effect of augmented renal clearance on the pharmacokinetics of piperacillin/tazobactam

niversity of Tartu0 个研究点目标入组 56 人开始时间: 2016年10月24日最近更新: 2017年4月3日

适应症

试验速览

暂无简介。

•1. Malignant or non-malignant haematological or oncological diagnosis
•2. Chemotherapy or immunosuppressive therapy administered within last 12 months
•3. Age from 6 months to 25 years
•4. Clinically indicated and ordinated treatment with piperacillin/tazobactam based on the discretion of treating physician
•5. Central venous, venous or arterial catheter inserted on clinical indications
•6. eGFRcr > 80 ml/min/1.73 m2
•7. Informed consent, if minor obtained from parents or legitimate representative of the child
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 49
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 7
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. History of allergic reactions to piperacillin/tazobactam, penicillin’s, or other ß-lactam antibiotics or iohexol
•2. Thyreotoxicosis
•3. Presence of external drain
•4. Ascites or generalised oedema
•5. Received chemotherapy or immunosuppressive therapy during the last 24 hours
•6. Received iohexol during last 24 hours
•7. Participation in any other clinical study of investigational drugs within 4 weeks

发起方

niversity of Tartu